Saturday, May 24, 2025

Curaleaf Sees Consensus Estimates Stay Flat After Q1 Results

Curaleaf Holdings (CSE: CURA) reported its first-quarter results on May 10th, beating the consensus estimates for their top line. The stock is up 3.5% since reporting its earnings. The company reported $260 million in revenue, up 13.1% quarter over quarter. The company additionally reported an outstandingly high 227.5% tax rate.

Analysts seem to still be digesting this quarter’s earnings with no change in Curaleaf’s consensus 12-month price target of C$27.86. Four analysts have strong buy ratings while the other ten analysts have buy ratings. BTIG has the street high at C$34 while Cormark Securities has the lowest at C$24.

In Haywood’s analyst note, their analyst Neal Gilmer reiterates his C$28 price target and buy rating on Curaleaf and he says that the reported numbers beat their expectations. Management guidance for the second quarter of $305-$315 million indicates a very strong revenue growth for the rest of the year.

Gilmer reiterates Curaleaf as their top pick as the company, “continues to perform well across key markets in the U.S and we expect continued positive momentum in the U.S.” You can see their updated key changes for 2021 and 2022 below.

Curaleaf’s revenue came in about 3% above Haywoods $253.2 million estimate and 1% higher in gross profit. Adjusted EBITDA was the largest line-item beat with Curaleaf reporting $62.6 million, 5% higher than the $59.9 million estimate Haywood had.

Forward-looking, the revenue guidance does wonder to set the stage for a strong second half of 2021 as the $300mln+ in quarterly revenue puts the company on a good track to hit its $1.2-$1.3 billion full-year guidance. Gilmer also expects that the companies additional capacity in key states will start to turn on in the second quarter, which will help them hit their full-year guidance. He adds, “The Q1 results demonstrate evidence of continued growth in key markets as well as new product introductions.”


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Leave a Reply

Video Articles

Toronto’s 2027 Condo Time Bomb: Financial Ruin for Pre-Construction Buyers | Mark Morris

Gold Industry Set For A $160 Billion Cash Haul In 2026!? | Terry Lynch – Power Metallic

$3200 Gold & The Miners Still Lagging!? | Cliff Hale-Sanders – Cerrado Gold

Recommended

Riverside Resources Spins Out Blue Jay Gold Corp

Canadian Copper Outlines $171 Million NPV, 36% IRR In PEA For Murray Brook And Caribou Complex

Related News

BMO Drops Cenovus Energy Price Target To $6.00 From $7.50

This morning BMO lowered its 12-month price target on Cenovus Energy (TSX: CVE) to C$6.00...

Friday, October 30, 2020, 11:22:00 AM

Cameco: Canaccord Anticipates Mixed Results For Q2 2022

Cameco (TSX: CCO) is expected to report its second quarter financial results on July 27...

Monday, July 25, 2022, 04:47:00 PM

Curaleaf To Acquire Reef Dispensaries For US$286 Million

It may have been delayed by two years, but it appears that Tryke Companies, whom...

Monday, November 8, 2021, 07:49:53 AM

BMO Lowers Maple Leaf Foods’ Earnings Estimates On Expected Headwinds

Maple Leaf Foods (TSX: MFI) is expected to report its second-quarter financial results on August...

Saturday, July 9, 2022, 03:17:00 PM

Cameco: Canaccord Refers To Firm As “Go-To” Name For Uranium Exposure

On February 9th, Cameco (TSX: CCO) reported its full-year 2021 financial results. The company reported...

Saturday, February 12, 2022, 02:03:00 PM